Short Interest Alert: Could Anavex Life Sciences Corporation (OTCMKTS:AVXL) Change Direction After Less Shorts?

November 25, 2016 - By Clifton Ray   ·   0 Comments

Short Interest Alert: Could Anavex Life Sciences Corporation (OTCMKTS:AVXL) Change Direction After Less Shorts?

The stock of Anavex Life Sciences Corporation (OTCMKTS:AVXL) registered a decrease of 9.13% in short interest. AVXL’s total short interest was 5.13M shares in November as published by FINRA. Its down 9.13% from 5.64M shares, reported previously. With 467,400 shares average volume, it will take short sellers 11 days to cover their AVXL’s short positions. The short interest to Anavex Life Sciences Corporation’s float is 15.36%. The stock last traded at $0 per share. It is down 28.44% since April 22, 2016 and is downtrending. It has underperformed by 33.84% the S&P500.

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The company has a market cap of $. The Firm is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative diseases, including drug candidates to treat Alzheimer’s disease , other central nervous system (CNS) diseases, pain and various types of cancer. It currently has negative earnings. The Company’s lead compounds ANAVEX 2-73 and ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), are being developed to treat AD and other CNS diseases.

AVXL Company Profile

Anavex Life Sciences Corp., incorporated on January 23, 2004, is a clinical-stage biopharmaceutical company. The Firm is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative diseases, including drug candidates to treat Alzheimer’s disease (AD), other central nervous system (CNS) diseases, pain and various types of cancer. The Company’s lead compounds, ANAVEX 2-73 and ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), are being developed to treat AD and other CNS diseases. The Company’s product pipeline also includes ANAVEX 3-71, ANAVEX 1-41 and ANAVEX 1037. The Company’s SIGMACEPTOR Discovery Platform produces small molecule drug candidates with modes of action, based on its understanding of sigma receptors. Sigma receptors may be targets for therapeutics to combat many human diseases, including AD.

More notable recent Anavex Life Sciences Corp (OTCMKTS:AVXL) news were published by: Fool.com which released: “Why Anavex Life Sciences Corp. Rocketed Higher Today” on September 28, 2016, also Fool.com with their article: “Why Anavex Life Sciences Corp. Just Imploded” published on July 27, 2016, Fool.com published: “Bull Vs. Bear: Anavex Life Sciences Corp.” on May 23, 2016. More interesting news about Anavex Life Sciences Corp (OTCMKTS:AVXL) were released by: Fool.com and their article: “Better Buy: Anavex Life Sciences Corp. vs. Ionis Pharmaceuticals, Inc.” published on October 05, 2016 as well as Fool.com‘s news article titled: “Better Buy: Anavex Life Sciences Corp. vs. Biogen” with publication date: June 09, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Clifton Ray


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>